These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10698557)

  • 21. The influence of poly(allylamine hydrochloride) hydrogel crosslinking density on its thermal and phosphate binding properties.
    Elsiddig R; O'Reilly NJ; Hudson SP; Owens E; Hughes H; O'Grady D; McLoughlin P
    Int J Pharm; 2022 Jun; 621():121806. PubMed ID: 35526696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metal ion and vitamin adsorption profiles of phosphate binder ion-exchange resins.
    Takagi K; Masuda K; Yamazaki M; Kiyohara C; Itoh S; Wasaki M; Inoue H
    Clin Nephrol; 2010 Jan; 73(1):30-5. PubMed ID: 20040349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastric pH, sevelamer hydrochloride and omeprazole.
    Capitanini A; Lupi A; Osteri F; Petrone I; Del Corso C; Straniti M; Gallieni M; Rossi A
    Clin Nephrol; 2005 Oct; 64(4):320-2. PubMed ID: 16240906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
    Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transient acid exposure increases sevelamer HCl phosphate binding.
    Ross EA; Scott WE; Odukale AA; Alba NA; Batich CD
    J Pharm Sci; 2007 Aug; 96(8):2154-60. PubMed ID: 17506513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
    Pai AB; Shepler BM
    Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperphosphatemia and phosphate binders.
    Schucker JJ; Ward KE
    Am J Health Syst Pharm; 2005 Nov; 62(22):2355-61. PubMed ID: 16278327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endotoxin-binding affinity of sevelamer hydrochloride.
    Perianayagam MC; Jaber BL
    Am J Nephrol; 2008; 28(5):802-7. PubMed ID: 18506105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the In Vitro Efficacy of Sevelamer Hydrochloride and Sevelamer Carbonate.
    Yang Y; Mohammad A; Berendt RT; Carlin A; Khan MA; Faustino PJ
    J Pharm Sci; 2016 Feb; 105(2):864-875. PubMed ID: 26219932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency.
    Nagano N; Miyata S; Obana S; Ozai M; Kobayashi N; Fukushima N; Burke SK; Wada M
    Nephrol Dial Transplant; 2001 Sep; 16(9):1870-8. PubMed ID: 11522872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis.
    Tzanno-Martins C; Biavo BM; Ferreira-Filho O; Ribeiro-Junior E; João-Luiz MV; Degaspari S; Scavone C; Kawamoto E
    Int J Immunopathol Pharmacol; 2014; 27(1):25-35. PubMed ID: 24674676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
    Pai AB; Smeeding JE; Brook RA
    Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children.
    Mahdavi H; Kuizon BD; Gales B; Wang HJ; Elashoff RM; Salusky IB
    Pediatr Nephrol; 2003 Dec; 18(12):1260-4. PubMed ID: 14586677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder.
    Nagano N; Miyata S; Obana S; Eto N; Fukushima N; Burke SK; Wada M
    Nephron; 2001 Nov; 89(3):321-8. PubMed ID: 11598397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of fatty acids on the phosphate binding of TRK-390, a novel, highly selective phosphate-binding polymer.
    Nakaki J; Yamaguchi S; Torii Y; Inoue A; Minakami S; Kanno T; Murakami M; Tsuzuki M; Mochizuki H; Suyama K; Miyamoto M
    Eur J Pharmacol; 2013 Aug; 714(1-3):312-7. PubMed ID: 23911881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children.
    Abdullah S; Diezi M; Sung L; Dupuis LL; Geary D; Abla O
    Pediatr Blood Cancer; 2008 Jul; 51(1):59-61. PubMed ID: 18240167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The crossover comparative trial of calcium acetate versus sevelamer hydrochloride (Renagel) as phosphate binders in dialysis patients.
    Fournier A; Oprisiu R; Albu AT; Dungaciu M; El Esper N; Mornière P
    Am J Kidney Dis; 2000 Jun; 35(6):1248-50. PubMed ID: 10877727
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders.
    Brewster UC; Ciampi MA; Abu-Alfa AK; Reilly RF
    Nephrology (Carlton); 2006 Apr; 11(2):142-6. PubMed ID: 16669977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.